News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Corning wins optical contracts and expands fiber capacity, strengthening cash-flow outlook as AI datacenter buildout accelerates.
  • SiTime's Renesas timing acquisition and recent beats set up a datacenter-driven revenue runway and potential mid-term re-rate.
  • Sandisk's $15.5B buyback could tighten memory supply and support a re-rate for Western Digital via pricing leverage.
  • Mirion's revenue acceleration and exposure to nuclear and medical detection create a defined-risk recovery trade opportunity.
  • Achieve Life Sciences' recent financing and elevated short interest make it a tactical dip-buy despite binary clinical risk.
  • Eva Live CEO bought 4.22 million GOAI shares, raising his stake above 23 million and signaling insider confidence.
  • Smith+Nephew launched the EVOS PELVIC Plating System in the US, expanding its orthopedic trauma product portfolio.

Latest Articles

Yext: Scout-Led Re-Acceleration Could Make $YEXT a Tactical Long

Yext: Scout-Led Re-Acceleration Could Make $YEXT a Tactical Long

Yext is a sub-$1B market-cap SaaS name where product evolution around a 'Scout' intelligent search layer could re-risk growth while valuation already discounts a muted outcome. The company generates positive free cash flow ($53M last reported), carries an enterprise value of roughly $591M and trades around $5.35. This trade targets a mid-term rebou…

What Every XFLT Shareholder Needs to Know for XFLT's Proxy Contest

What Every XFLT Shareholder Needs to Know for XFLT's Proxy Contest

XAI Investments LLC, manager of XAI Floating Rate & Alternative Income Trust (XFLT), addresses shareholder concerns amidst a proxy contest regarding the approval of a new sub-advisory agreement with King Street Capital Management. The firm refutes claims from the terminated sub-adviser Octagon about fee increases and highlights Octagon's poor perfo…

Buy STIM on Growth and Cheap P/S; Watch Margins and Cash Flow

Buy STIM on Growth and Cheap P/S; Watch Margins and Cash Flow

Neuronetics (STIM) is a small-cap medical technology name with accelerating revenue drivers in transcranial magnetic stimulation (TMS) and an attractive price-to-sales of 0.74. The stock trades near $1.62 with an enterprise value of roughly $160.8M, leaving room for a re-rate if adoption and reimbursement continue to improve. However, negative marg…

IBM After the Z Shock: A Defensive Long With a Tactical Entry

IBM After the Z Shock: A Defensive Long With a Tactical Entry

IBM plunged after a surprise weakness in its Z mainframe business, but the stock now trades near the 52-week low with a 3%+ yield, healthy free cash flow and an attractive risk/reward for long-term holders who can stomach near-term execution risk. This trade idea lays out an entry at $212.66, a stop at $198.00 and a 180-trading-day target of $280.0…

ASML: Buy into the AI Capex Cycle — A 180-Day Trade Plan

ASML: Buy into the AI Capex Cycle — A 180-Day Trade Plan

ASML sits at the center of the AI infrastructure build-out. Recent results show accelerating revenue and a 2026 guide lift to €43-45B, while management is committing to a 30% capacity increase now (with another potential 30% in 2028). That combination of structural demand and supply-constrained positioning supports a long trade with a 180-trading-d…

Assembly Biosciences: Gilead Partnership and Clinical Optionality Make ASMB a Leverage Play on Next-Gen Antivirals

Assembly Biosciences: Gilead Partnership and Clinical Optionality Make ASMB a Leverage Play on Next-Gen Antivirals

Assembly Biosciences (ASMB) offers a way to play a concentrated biotech bet with a strong strategic partner. With positive Phase 1b readouts for two long-acting helicase-primase inhibitors, a Gilead collaboration, and cash into 2028, the stock ($26.81) already discounts some risk but not all of the upside from Phase 2 starts and potential deal flow…

Tactical Long on RDW: Buy the Dilution Dip After a 65% Retreat

Tactical Long on RDW: Buy the Dilution Dip After a 65% Retreat

Redwire (RDW) has been punished since its late-May peak as an announced $500M at-the-market offering and sector rotation into SpaceX hammered the stock. At roughly $8.50 and a $2.02B market cap, the company still shows strong top-line momentum and a sizable backlog, while balance-sheet leverage is manageable. This is a tactical long with tight risk…

Acco Brands: Cheap, Cash-Generating, and Set Up for a Controlled Rebound

Acco Brands: Cheap, Cash-Generating, and Set Up for a Controlled Rebound

<p>Acco Brands (ACCO) trades at bargain multiples, throws off free cash flow of roughly $49M, and yields over 7% — metrics that argue for a constructive long trade on weakness. The company is small-cap, levered, and exposed to cyclical end markets, so position sizing and a clear stop are essential. This idea targets a measured rebound toward prior …

WeRide Named Among China's Top 10 AI Case Studies for UAE Autonomous Driving Deployment, the Only Autonomous Driving Company Recognized

WeRide Named Among China's Top 10 AI Case Studies for UAE Autonomous Driving Deployment, the Only Autonomous Driving Company Recognized

WeRide has been named one of China's top 10 AI international cooperation case studies due to its successful deployment of fully driverless Robotaxi services in the UAE. The company is the only autonomous driving firm on the list, showcasing its leadership in commercializing autonomous mobility globally. Operating in multiple UAE emirates with exten…

BJ's Restaurants: Appetite for More After a Strong Breakout

BJ's Restaurants: Appetite for More After a Strong Breakout

BJ's Restaurants (BJRI) has ripped to fresh 52-week highs on heavy volume, but the move is backed by solid profitability, healthy free cash flow and a conservative balance sheet. The stock looks actionable on a mid-term (45 trading days) swing with a clear entry, stop and target that balances momentum with valuation discipline.

MKDWELL Tech Inc. to Acquire Premium Smart-Home and IoT Group, Diversifying Beyond Automotive Electronics

MKDWELL Tech Inc. to Acquire Premium Smart-Home and IoT Group, Diversifying Beyond Automotive Electronics

MKDWELL Tech Inc., listed on Nasdaq (MKDW), has announced the acquisition of Landvision Inc., a developer of AI-enabled smart-home and IoT products. This acquisition will diversify MKDWELL's business from automotive electronics to the growing smart-home sector, leveraging complementary strengths in embedded electronics and manufacturing. The deal i…

Erasca (ERAS): A Buy at the Backdoor to RAS Inhibitor Competition

Erasca (ERAS): A Buy at the Backdoor to RAS Inhibitor Competition

Erasca has the science, a modality-agnostic RAS/MAPK pipeline and fresh capital. Recent legal and clinical setbacks pushed sentiment into the gutter; that creates a trading opportunity for investors willing to take event risk. This trade targets a mid-term recovery if the company executes on clinical updates and the patent dispute does not derail d…